BIOFRONTERA INC (BFRI)
US09077D2099 - Common Stock
Taking everything into account, BFRI scores 3 out of 10 in our fundamental rating. BFRI was compared to 194 industry peers in the Pharmaceuticals industry. BFRI has a bad profitability rating. Also its financial health evaluation is rather negative. BFRI shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BFRI has reported negative net income.
In the past year BFRI has reported a negative cash flow from operations.
In the past 5 years BFRI always reported negative net income.
In the past 5 years BFRI always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -62.61%, BFRI is not doing good in the industry: 69.27% of the companies in the same industry are doing better.
With a Return On Equity value of -123.80%, BFRI is not doing good in the industry: 64.58% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.61% | ||
| ROE | -123.8% | ||
| ROIC | N/A |
ROA(3y)-48.06%
ROA(5y)-45.58%
ROE(3y)-251.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BFRI has a better Gross Margin (47.75%) than 61.46% of its industry peers.
BFRI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.02%
GM growth 5YN/A
2. Health
2.1 Basic Checks
BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BFRI has more shares outstanding than it did 1 year ago.
BFRI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -7.63, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
BFRI has a Altman-Z score of -7.63. This is in the lower half of the industry: BFRI underperforms 70.83% of its industry peers.
BFRI has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
BFRI has a Debt to Equity ratio (0.03) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.63 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
BFRI has a Current Ratio of 1.89. This is a normal value and indicates that BFRI is financially healthy and should not expect problems in meeting its short term obligations.
BFRI's Current ratio of 1.89 is on the low side compared to the rest of the industry. BFRI is outperformed by 63.54% of its industry peers.
BFRI has a Quick Ratio of 1.46. This is a normal value and indicates that BFRI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.46, BFRI is doing worse than 68.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.46 |
3. Growth
3.1 Past
BFRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.42%, which is quite impressive.
BFRI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.84%.
The Revenue has been growing by 21.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)72.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
Revenue 1Y (TTM)18.84%
Revenue growth 3Y21.81%
Revenue growth 5YN/A
Sales Q2Q%1.28%
3.2 Future
BFRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.05% yearly.
The Revenue is expected to grow by 25.87% on average over the next years. This is a very strong growth
EPS Next Y82.98%
EPS Next 2Y39.8%
EPS Next 3Y26.05%
EPS Next 5YN/A
Revenue Next Year13.64%
Revenue Next 2Y16.86%
Revenue Next 3Y19.72%
Revenue Next 5Y25.87%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BFRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BFRI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BFRI's earnings are expected to grow with 26.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.8%
EPS Next 3Y26.05%
5. Dividend
5.1 Amount
No dividends for BFRI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOFRONTERA INC
NASDAQ:BFRI (11/21/2024, 8:14:44 PM)
After market: 0.7451 -0.01 (-1.83%)0.759
-0.02 (-2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.61% | ||
| ROE | -123.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)72.42%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y82.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.84%
Revenue growth 3Y21.81%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y